LLY

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

Eli Lilly and Company (NYSE: LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance.

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Eli Lilly continues strong execution, exceeding revenue expectations and expanding its pipeline with strategic, low-risk acquisitions in infectious diseases...

Novo Nordisk A/S is closing in on Eli Lilly in the GLP-1 market despite Ozempic declines. Click for this NVO stock update.

Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

Eli Lilly's robust guidance despite higher costs on acquisitions and underwhelming performance by Foundayo indicates its strength. See why LLY stock is a Strong Buy.